1. Home
  2. TBPH vs TYG Comparison

TBPH vs TYG Comparison

Compare TBPH & TYG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

N/A

Current Price

$19.26

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Logo Tortoise Energy Infrastructure Corporation

TYG

Tortoise Energy Infrastructure Corporation

N/A

Current Price

$49.85

Market Cap

882.2M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
TBPH
TYG
Founded
2013
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
882.2M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
TBPH
TYG
Price
$19.26
$49.85
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$27.80
N/A
AVG Volume (30 Days)
386.5K
103.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
11.43%
EPS Growth
N/A
N/A
EPS
0.88
N/A
Revenue
$15,386,000.00
N/A
Revenue This Year
$70.90
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$21.66
$52.62
Revenue Growth
N/A
N/A
52 Week Low
$7.90
$33.73
52 Week High
$21.03
$49.86

Technical Indicators

Market Signals
Indicator
TBPH
TYG
Relative Strength Index (RSI) 45.07 74.85
Support Level $18.27 $42.25
Resistance Level $19.04 N/A
Average True Range (ATR) 0.91 0.83
MACD -0.09 0.19
Stochastic Oscillator 23.72 94.21

Price Performance

Historical Comparison
TBPH
TYG

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About TYG Tortoise Energy Infrastructure Corporation

Tortoise Energy Infrastructure Corp seeks to provide a high level of current income to stockholders. It invests in fixed-income and dividend-paying equity securities of power and energy infrastructure companies that provide stable and defensive characteristics throughout economic cycles.

Share on Social Networks: